Lungs News and Research

RSS

Experts highlight latest advances in use of biomarkers in various diseases

Over the last few decades there has been an explosion in the discovery of biomarkers for diagnosis, disease monitoring, and prognostic evaluation. In the April issue of Translational Research, entitled "Biomarkers: New Tools of Modern Medicine," an international group of medical experts explores the promise and challenges of biomarker discovery and highlights the latest advances in the use of biomarkers in various diseases.

16 Mar 2012

CYFRA reliable marker for response to chemotherapy for NSCLC

Researchers found that CYFRA and change in levels of CYFRA were found to be reliable markers for response to chemotherapy for non-small cell lung cancer (NSCLC) in a study of 88 patients. Research presented in the April 2012 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology shows that this marker can be used to determine whether or not a patient should continue a particular chemotherapy regimen.

16 Mar 2012

UM, Shock Trauma partner to train dental students, residents

The University of Maryland's (UM) School of Dentistry has teamed up with the UM School of Medicine's R Adams Cowley Shock Trauma Center for training future dentists to respond efficiently and effectively to life threatening medical emergencies in a dental setting.

16 Mar 2012

Panel of 10 serum protein biomarkers could help in lung cancer diagnosis

A panel of serum biomarkers could help predict the level of lung cancer risk in high-risk patients, offering doctors an option before proceeding with a biopsy. Research presented in the April 2012 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology shows that a panel of 10 serum protein biomarkers could help in the lung cancer diagnosis.

16 Mar 2012

Patients with early stage MPM may be eligible for aggressive multi-modality therapy

Patients with early stage malignant pleural mesothelioma (MPM), a cancer that develops in the lining of the lungs, may be eligible for aggressive multi-modality therapy involving surgery, radiotherapy and chemotherapy.

16 Mar 2012

New technique can sensitize cancer cells to radiation

Researchers at Winship Cancer Institute are developing a technique to remove cancer cells' defenses against radiation.

16 Mar 2012

Nearly 800,000 lung cancer deaths prevented due to tobacco control efforts

Declines in cigarette smoking among Americans since the mid-1950s - particularly since tobacco-control policies and interventions were implemented after the U.S. Surgeon General's Report on Smoking and Health was released in 1964 - prevented nearly 800,000 lung cancer deaths between 1975 and 2000, according to a study led by researchers at Fred Hutchinson Cancer Research Center.

15 Mar 2012

Scientists discover cells that chaperone food antigens in the intestine

With every meal, immune cells in the intestine stand like sentries at a citadel, turning away harmful bacteria but allowing vitamins and nutrients to pass. Now, researchers at Washington University School of Medicine in St. Louis have identified the cells that chaperone food antigens, or proteins, in the intestine so that the immune system doesn't mount an attack.

15 Mar 2012

Potential new way to treat rare inherited metabolic disorders

A University of Michigan cell biologist and his colleagues have identified a potential drug that speeds up trash removal from the cell's recycling center, the lysosome.

14 Mar 2012

Modified Citrus Pectin binds and blocks harmful effects of Galectin-3

Galectin-3 sounds like a planet out of "Star Trek," but it can be much more ominous. Recently, distinguished integrative physician Isaac Eliaz, M.D., presented breakthrough research demonstrating that the protein Galectin-3 is an active biomarker for numerous life-threatening diseases. Even more importantly, Dr. Eliaz showed how Modified Citrus Pectin (MCP) binds and blocks Galectin-3 throughout the body.

14 Mar 2012

Insmed fourth quarter revenues increase to $1.4 million

Insmed Incorporated, a biopharmaceutical company, today reported results for the fourth quarter and fiscal year ended December 31, 2011.

13 Mar 2012

Agennix, DSM sign new contract to manufacture talactoferrin for NSCLC

DSM Pharmaceutical Products, the custom manufacturing business of Royal DSM N.V., and Agennix AG have signed a new contract under which DSM will continue to manufacture talactoferrin for Agennix at commercial levels.

13 Mar 2012

RhoGDI2 protein helps prevent bladder cancer metastasis to the lungs

The diagnosis of localized bladder cancer carries an 80 percent five-year survival rate, but once the cancer spreads, the survival rate at even three years is only 20 percent. A major study published today in the Journal of Clinical Investigation not only shows how bladder cancer metastasizes to the lungs but pinpoints a method for stopping this spread.

13 Mar 2012

Scientists develop realistic model to explain cellular signal processing

Scientists at the Charité - Universitätsmedizin Berlin and the US National Institutes of Health (NIH) have developed a realistic model for explaining cellular signal processing.

13 Mar 2012

New research could provide roadmap for more effective drug discovery for CF

A recent study led by Gergely Lukacs, a professor at McGill University's Faculty of Medicine, Department of Physiology, and published in the January issue of Cell, has shown that restoring normal function to the mutant gene product responsible for cystic fibrosis (CF) requires correcting two distinct structural defects. This finding could point to more effective therapeutic strategies for CF in the future.

12 Mar 2012

FDA clears Aradigm IND for Pulmaquin Phase 3 clinical trial in non-cystic fibrosis BE

Aradigm Corporation today announced that the Company's Investigational New Drug Application (IND) to conduct a pivotal Phase 3 clinical trial of Pulmaquin (dual release ciprofloxacin for inhalation) in non-cystic fibrosis bronchiectasis (BE) has been cleared by the U.S. Food and Drug Administration.

12 Mar 2012

Korean FDA grants pre-market clearance for ETView's VivaSight‐SL airway management solutions

ETView today announced that the Korean Food and Drug Administration ("KFDA") has granted pre-market clearance for VivaSight‐SL. With KFDA clearance, ETView plans to immediately initiate market launch of VivaSight‐SL. ETView also announced a distribution agreement with ChinooMTech Company.

12 Mar 2012

Cancer rates to fall among men but slightly rise among women by 2020: Report

The report says that due to the growing and ageing population the actual number of new cases will rise by almost 40 per cent on 2007 levels. But when that's converted to the number of cases per 100,000 people the results are surprising. Cancer rates in men will fall from 595 to 568 cases per 100,000 by 2020. That equates to about 85,000 cases. When it comes to women the rate is projected to rise from 394 to 408 cases per 100,000. That's equivalent to 65,000 new cases in 2020.

11 Mar 2012

Gene that causes aggression in men under stress discovered

Scientists have found that “macho” gene that makes men behave more aggressively than women under stress. They say this one gene could explain why men have a 'fight or flight' response while women are more likely to try and defuse the situation. The study has been published in the journal BioEssays.

11 Mar 2012

New ways of delivering personalized cancer therapies in a cost effective manner

As scientists continue making breakthroughs in personalized cancer treatment, delivering those therapies in the most cost effective manner has become increasingly important. Now researchers at the University of Colorado School of Medicine have identified new ways of doing just that, allowing more patients to benefit from this revolution in cancer care.

11 Mar 2012